Business Segments · Goodwill

Neuroscience — Goodwill

Medtronic Neuroscience — Goodwill increased by 0.2% to $11.76B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $11.61B to $11.76B. Over 3 years (FY 2022 to FY 2025), Neuroscience — Goodwill shows relatively stable performance with a 0.9% CAGR.

Analysis

StatementSegment
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ2 2019
Last reportedQ1 2026
Rolls up toGoodwill

How to read this metric

A decrease in goodwill typically signals an impairment charge, indicating that the value of past acquisitions has declined.

Detailed definition

This represents the excess of the purchase price over the fair value of net assets acquired in previous acquisitions wit...

Peer comparison

Comparable to goodwill balances reported by peers following M&A activity.

Metric ID: mdt_segment_neuroscience_goodwill

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$11.30B$11.26B$11.27B$11.24B$11.13B$11.66B$11.58B$11.73B$11.72B$11.71B$11.63B$11.67B$11.64B$11.65B$11.67B$11.61B$11.72B$11.75B$11.74B$11.76B
QoQ Change-0.4%+0.1%-0.3%-0.9%+4.8%-0.7%+1.3%-0.1%-0.1%-0.7%+0.3%-0.3%+0.1%+0.1%-0.5%+0.9%+0.3%-0.1%+0.2%
YoY Change-1.5%+3.6%+2.8%+4.4%+5.3%+0.4%+0.5%-0.5%-0.6%-0.5%+0.3%-0.5%+0.6%+0.9%+0.6%+1.3%
Range$11.13B$11.76B
CAGR+0.8%
Avg YoY Growth+1.1%
Median YoY Growth+0.5%

Frequently Asked Questions

What is Medtronic's neuroscience — goodwill?
Medtronic (MDT) reported neuroscience — goodwill of $11.76B in Q1 2026.
How has Medtronic's neuroscience — goodwill changed year-over-year?
Medtronic's neuroscience — goodwill increased by 1.3% year-over-year, from $11.61B to $11.76B.
What is the long-term trend for Medtronic's neuroscience — goodwill?
Over 3 years (2022 to 2025), Medtronic's neuroscience — goodwill has grown at a 0.9% compound annual growth rate (CAGR), from $45.61B to $46.82B.
What does neuroscience — goodwill mean?
The value of past acquisitions attributed to the neuroscience segment.